Cyberknife Radiosurgery Boost for Hilar Cholangiocarcinoma (Klatskin Tumor)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00630890|
Recruitment Status : Terminated (investigator left UCSF and study was closed prematurely in 2008. No results to report.)
First Posted : March 7, 2008
Last Update Posted : September 11, 2015
The purpose of this study is to test the safety of giving external beam radiation, followed by a Cyberknife radiosurgery boost at different dose levels, together with a chemotherapy drug called capecitabine. The dose of Cyberknife radiosurgery boost will be made higher slowly in this protocol. Patients with hilar cholangiocarcinoma (Klatskin tumor), which is not amenable for surgical removal, are eligible.
The hypothesis is that highly focused high dose radiation delivered using Cyberknife in conjunction with traditional radiation and chemotherapy can improve outcome in this patient population.
|Condition or disease||Intervention/treatment||Phase|
|Cholangiocarcinoma Klatskin Tumor Biliary Tract Cancer||Radiation: External beam radiation and Cyberknife radiosurgery boost and capecitabine||Phase 1|
This is a dose escalation study which will escalate the dose of Cyberknife radiosurgery boost after external beam radiation of 45 Gy with concurrent capecitabine. The three dose levels are 4 Gy x5, 5 Gy x5 and 6 Gy x 5, with 3 patients at each dose level. Dose-limiting toxicity (DLT) is defined as acute grade 3 liver or intestinal toxicity or any acute grade 4 toxicity. If one patient experienced a DLT at a particular dose level, the cohort should be expanded to 6 patients. The maximum tolerated dose (MTD) is defined as the dose level below that which results in DLT in 2 or more of the 6 patients in each cohort. At least 5 patients should be enrolled in the cohort of 6 Gy x 5 even if none of the first 3 experienced DLT, as a means of added verification of dose tolerance, at this upper limit of dose for this study.
The patient population includes any patients who have unresectable hilar cholangiocarcinoma without any prior history of radiation. We anticipate accruing 1 patient every 2 months; therefore, we estimate that it will require approximately 22 months to accrue 11 patients if no DLT is experienced by any patients requiring expansion of the cohorts.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||11 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor)|
|Study Start Date :||October 2007|
|Actual Primary Completion Date :||December 2008|
|Actual Study Completion Date :||December 2008|
External beam radiation with Cyberknife radiosurgery boost and concurrent capecitabine
Radiation: External beam radiation and Cyberknife radiosurgery boost and capecitabine
External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
Other Name: Xeloda
- To evaluate acute toxicities [ Time Frame: 3 months for acute toxicities ]
- To determine the maximal tolerated dose of the Cyberknife radiosurgery boost [ Time Frame: 3 months for acute toxicities ]
- To assess local and regional control [ Time Frame: two years ]
- To evaluate radiographic response [ Time Frame: two years ]
- To assess delayed and long-term toxicities [ Time Frame: two years ]
- To estimate disease specific and overall survival [ Time Frame: two years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00630890
|United States, California|
|University of California San Francisco|
|San Francisco, California, United States, 94143-0226|
|Principal Investigator:||Kim Huang, M.D.||University of California, San Francisco|